Johnson & Johnson Innovative Medicine

Our scientists are collaborating with Bristol Myers Squibb to find new ways to reduce the risk of heart attacks and strokes for those with thrombotic conditions. Together, our combined dedication to advance cardiovascular care continues to power our Phase 3 Librexia program.   As we join our industry peers at #ACC25, our Factor XIa research is top of mind. 

New data at #ELCC25 reinforce our commitment to developing patient-first treatments that have the potential to transform #LungCancer care. See how we’re driving progress: https://lnkd.in/evSv_uRQ #NSCLC #JNJOncology

Next week, we’re headed to the AD/PD - Advances in Science & Therapy International Conference in Vienna, Austria, where we’ll be presenting data from our pipeline and novel approaches in Alzheimer’s disease (AD). We’ll also be hosting a symposium where experts will discuss the latest data in Alzheimer’s disease (AD) that links pathological tau to neurodegeneration and exploring potential use cases for how this data could advance the field. Deepening our understanding of AD pathology is essential for developing potential therapeutic options that can make a meaningful difference for patients and their families, and we look forward to learning from and sharing with the AD community. Whether you plan to attend AD/PD next week in person or virtually, join the symposium on April 3—details below—to learn more about ongoing research in AD. #AlzheimersDisease #ADPD2025 #JNJNeuroscience

At Johnson & Johnson, we’re committed to making a meaningful difference for people living with #LungCancer. New data show how our targeted therapy has the potential to change the way EGFR-mutated non-small cell lung cancer (NSCLC) is treated.     See how we’re driving progress at #ELCC25: https://lnkd.in/ewxnX6nW   #JNJOncology #NSCLC 

Fetal and neonatal alloimmune thrombocytopenia (#FNAIT) is a rare condition affecting an estimated 1 in 1,000 pregnancies, in which a pregnant person’s immune system attacks the fetus or newborn’s platelets. Despite the life-threatening risks associated with this disease, it is not routinely screened for in pregnancy and remains underdiagnosed. This FNAIT Awareness Week, hear Ashley’s powerful message on the importance of self-advocacy when something feels off. Learn more about our dedication to addressing the critical unmet need in FNAIT here: https://lnkd.in/e6kjtzJs #JNJImmunology #MaternalFetalHealth

Cardiovascular diseases are the leading cause of death worldwide. At this week’s American College of Cardiology congress, our team looks forward to sharing how we’re driving science and innovation to improve outcomes for patients living with cardiovascular disease and pulmonary hypertension. #ACC25 Learn more here: https://lnkd.in/efUtsnzt

We’re presenting new data at the 2025 American Academy of Neurology Annual Meeting. Highlighting our autoantibody research and robust pipeline focused on generalized myasthenia gravis (gMG), these presentations will emphasize our efforts to address the significant unmet needs that the gMG community face, and the potential for advanced, transformative therapies. Learn more about how our latest findings aim to set new standards in gMG patient care: https://lnkd.in/eGY-fRCQ #JNJImmunology #JNJNeuroscience

Warm autoimmune hemolytic anemia (wAIHA) is a rare and challenging disease where the immune system mistakenly attacks and destroys red blood cells.  The journey to diagnosis can take months, and once identified, finding effective treatments can be difficult, leaving patients with an ongoing sense of uncertainty about what lies ahead. This #AIHAAwarenessDay, together with passionate advocates like the wAIHA Warriors, we want to amplify voices like Azreen’s, who shares a powerful story of resilience following her wAIHA diagnosis.  Visit the link to hear more about her story: https://lnkd.in/ehSbph5c #JNJImmunology

Crohn’s disease affects millions of people globally, but each patient’s journey and their needs are unique. Treatment options should reflect that. Melodie Narain-Blackwell, founder of Color of Gastrointestinal Illnesses (COGI), shares why the recent FDA approval of our advanced therapy for adults living with moderately to severely active Crohn’s disease is meaningful for the inflammatory bowel disease (IBD) community. Learn more about our recently approved treatment option: https://lnkd.in/e2RuyYZP #JNJImmunology

NEWS: Today we officially break ground on our new biologics manufacturing facility in Wilson, North Carolina. This 500,000 square foot state-of-the-art facility will create more than 5,000 high-wage manufacturing and construction jobs while helping to deliver transformational medicines for people living with cancer, immune-mediated, and neurological diseases. Learn more about the new site and our investment: https://bit.ly/4bOMjxB #JNJSupplyChain #Manufacturing